IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
IceCure expects to report that U.S. revenue for ProSense systems and cryoprobes increased more than 30% in Q1 2026 compared to the prior year, driven by adoption following the October 2025 FDA clearance. The company is expanding its installed base at leading academic hospitals and anticipates closing new system sales in Q2.
Key figures
- Revenue Yoy
- more than 30%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.